Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 452

1.

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.

Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Brosgart CL, Borroto-Esoda K, Arterburn S, Chuck SL; Adefovir Dipivoxil 438 Study Group.

Gastroenterology. 2006 Dec;131(6):1743-51. Epub 2006 Sep 20.

PMID:
17087951
2.

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Arterburn S, Xiong S, Currie G, Brosgart CL; Adefovir Dipivoxil 438 Study Group.

N Engl J Med. 2005 Jun 30;352(26):2673-81.

3.

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F.

N Engl J Med. 2008 Dec 4;359(23):2442-55. doi: 10.1056/NEJMoa0802878.

4.

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL; Adefovir Dipivoxil 437 Study Group.

N Engl J Med. 2003 Feb 27;348(9):808-16.

5.

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL; Adefovir Dipivoxil 438 Study Group.

N Engl J Med. 2003 Feb 27;348(9):800-7. Erratum in: N Engl J Med. 2003 Mar 20;348(12):1192.

6.

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

Marcellin P, Chang TT, Lim SG, Sievert W, Tong M, Arterburn S, Borroto-Esoda K, Frederick D, Rousseau F.

Hepatology. 2008 Sep;48(3):750-8. doi: 10.1002/hep.22414.

PMID:
18752330
7.

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.

Peters MG, Hann Hw Hw, Martin P, Heathcote EJ, Buggisch P, Rubin R, Bourliere M, Kowdley K, Trepo C, Gray Df Df, Sullivan M, Kleber K, Ebrahimi R, Xiong S, Brosgart CL.

Gastroenterology. 2004 Jan;126(1):91-101.

PMID:
14699491
8.

Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.

Pellicelli AM, Barbaro G, Francavilla R, Romano M, Barbarini G, Mazzoni E, Mecenate F, Paffetti A, Barlattani A, Struglia C, Villani R, Nauri L, Nosotti L, Armignacco O, Ferri F, Camporiondo MP, Soccorsi F; Club Epatologi Ospedalieri (CLEO) Group.

Clin Ther. 2008 Feb;30(2):317-23. doi: 10.1016/j.clinthera.2008.02.012.

PMID:
18343270
9.

[Three year adefovir dipivoxil treatment for hepatitis B e antigen-positive chronic hepatitis B patients].

Ling N, Zhou Z, Zhang DZ, Ren H.

Zhonghua Gan Zang Bing Za Zhi. 2007 May;15(5):346-9. Chinese.

PMID:
17524266
10.

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Gurel S, Snow-Lampart A, Borroto-Esoda K, Mondou E, Anderson J, Sorbel J, Rousseau F.

Gastroenterology. 2011 Jan;140(1):132-43. doi: 10.1053/j.gastro.2010.10.011. Epub 2010 Oct 16.

PMID:
20955704
11.

[A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period].

Yang Q, Gong ZJ, Hu DF.

Zhonghua Gan Zang Bing Za Zhi. 2009 Jul;17(7):515-9. Chinese.

PMID:
19912686
12.

A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection.

Gilson RJ, Chopra KB, Newell AM, Murray-Lyon IM, Nelson MR, Rice SJ, Tedder RS, Toole J, Jaffe HS, Weller IV.

J Viral Hepat. 1999 Sep;6(5):387-95.

PMID:
10607255
13.

Sustained hepatitis B e antigen seroconversion in patients with chronic hepatitis B after adefovir dipivoxil treatment: analysis of precore and basal core promoter mutants.

Wu IC, Shiffman ML, Tong MJ, Marcellin P, Mondou E, Frederick D, Snow-Lampart A, Sorbel J, Rousseau F, Chang TT.

Clin Infect Dis. 2008 Nov 15;47(10):1305-11. doi: 10.1086/592570.

PMID:
18840078
14.

96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B.

Hui CK, Zhang HY, Bowden S, Locarnini S, Luk JM, Leung KW, Yueng YH, Wong A, Rousseau F, Yuen KY, Naoumov NN, Lau GK.

J Hepatol. 2008 May;48(5):714-20. doi: 10.1016/j.jhep.2007.10.013. Epub 2007 Dec 31.

PMID:
18207280
16.

Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial.

Chan HL, Heathcote EJ, Marcellin P, Lai CL, Cho M, Moon YM, Chao YC, Myers RP, Minuk GY, Jeffers L, Sievert W, Bzowej N, Harb G, Kaiser R, Qiao XJ, Brown NA; 018 Study Group.

Ann Intern Med. 2007 Dec 4;147(11):745-54. Epub 2007 Oct 1.

PMID:
17909201
17.

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus.

Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, Moorat A, Gardner S, Woessner M, Bourne E, Brosgart CL, Schiff E.

Gastroenterology. 2004 Jan;126(1):81-90.

PMID:
14699490
18.

Five years of treatment with adefovir dipivoxil in Chinese patients with HBeAg-positive chronic hepatitis B.

Minde Z, Yimin M, Guangbi Y, JinLin H, Hao W, Hong R, Yuming W, Xiaqiu Z, Daozhen X, Yagang C, Junqi N, Youming C, Yaozong W, Dixon J, Barker K.

Liver Int. 2012 Jan;32(1):137-46. doi: 10.1111/j.1478-3231.2011.02641.x. Epub 2011 Sep 19.

PMID:
22097972
19.

Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B.

Jonas MM, Kelly D, Pollack H, Mizerski J, Sorbel J, Frederick D, Mondou E, Rousseau F, Sokal E.

Hepatology. 2008 Jun;47(6):1863-71. doi: 10.1002/hep.22250.

PMID:
18433023
20.

A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B.

Zeng M, Mao Y, Yao G, Wang H, Hou J, Wang Y, Ji BN, Chang CN, Barker KF.

Hepatology. 2006 Jul;44(1):108-16.

PMID:
16799983

Supplemental Content

Support Center